Related Experiment Video
Updated: Jul 21, 2025
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
Published on: November 19, 2020
Comprehensive Risk Analysis of the Wingspan Stent in Relation to Target Vessels
Hiroo Yamaga1,2, Yusuke Tsuboko3,4, Tomoaki Terada2
1Cooperative Major in Advanced Biomedical Sciences, Joint Graduate School of Tokyo Women's Medical University and Waseda University, Waseda University, Tokyo, Japan.
Insights
The Stenting versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial led to safer use of the Wingspan stent. Modified indications reduced the risk of 30-day stroke or death after stent placement.
Area of Science:
- Neurology
- Interventional Neuroradiology
- Clinical Trials
Background:
- The Wingspan stent is used for intracranial stenosis, but its safety profile requires ongoing evaluation.
- The Stenting versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial significantly impacted treatment guidelines.
- Understanding the evolution of 30-day stroke or death rates associated with the Wingspan stent is crucial for patient safety.
Purpose of the Study:
- To analyze the incidence of 30-day stroke or death before and after the SAMMPRIS trial for Wingspan stent use.
- To compare stroke or death rates across different intracranial vessels (ICA, MCA, BA, VA) in relation to the SAMMPRIS trial.
- To assess the effectiveness of modified Wingspan stent indications in improving patient outcomes.
Main Methods:
- A comprehensive literature search was conducted across major databases (MEDLINE, Embase, Web of Science, Cochrane Library).
- Thirty studies (15 pre-SAMMPRIS, 15 post-SAMMPRIS) involving 2071 patients were included in the analysis.
- Forest plots and funnel plots were used to compare the incidence rates of 30-day stroke or death.
Main Results:
- Post-SAMMPRIS studies demonstrated a significantly lower incidence of 30-day stroke or death (5.6%) compared to pre-SAMMPRIS studies (8.5%), with an odds ratio of 0.64 (p=0.014).
- Lower event rates were observed post-SAMMPRIS for middle cerebral artery (MCA) and vertebral artery (VA) treatments.
- Overall incidence rates for ischemic and hemorrhagic stroke were 3.5% and 2.0%, respectively.
Conclusions:
- The modification of Wingspan stent indications following the SAMMPRIS trial has effectively reduced the incidence of 30-day stroke or death.
- These findings support the updated guidelines for the safe and effective use of the Wingspan stent in managing intracranial stenosis.
Objective:
To facilitate understanding for the safe use of the Wingspan stent, a comprehensive literature analysis was conducted, and incidence rates of 30-day stroke or death before and after the Stenting versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial were compared. We also investigated the associations between 30-day stroke or death rate and four lesion vessels, the internal carotid artery (ICA), middle cerebral artery (MCA), basilar artery (BA), and vertebral artery (VA).
Methods:
We searched MEDLINE, Embase, Web of Science, and Cochrane Library databases. The incidence rates of 30-day stroke or death in pre- and post-SAMMPRIS were compared using forest plots and funnel plots.
Results:
Thirty studies (15 before and 15 after the SAMMPRIS) were identified, comprising 2071 patients. Post-SAMMPRIS studies showed lower incidence rates of 30-day stroke or death compared to the pre-SAMMPRIS studies (8.5% vs. 5.6%, p = 0.014). The odds ratio of 30-day stroke or death of the post-SAMMPRIS group compared to that of the pre-SAMMPRIS group was 0.64 (95% confidence interval: 0.45-0.92, p = 0.014). The average 30-day stroke or death rates of overall, pre-, and post-SAMMPIS studies were 1.1%, 1.1%, and 1.1% for ICA; 6.2%, 8.8%, and 5.3% for MCA; 0.9%, 6.0%, and 2.7% for VA; and 13.5%, 15.1%, and 12.5% for BA, respectively. The post-SAMMPRIS study group showed significantly lower event rates for the treatment of MCA and VA than the pre-SAMMPRIS group did (p = 0.003 and p = 0.006, respectively). The incidence rates of ischemic and hemorrhagic stroke were 3.5% and 2.0%, respectively.
Conclusion:
This systematic surveillance study indicated that the modification of the indications for use based on the results of the SAMMPRIS trial for the Wingspan stent was effective in reducing 30-day stroke or death.
More Related Videos
08:28Monitoring the Wall Mechanics During Stent Deployment in a Vessel
Published on: May 8, 2012
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023